466 related articles for article (PubMed ID: 20507310)
1. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction.
Kerkhoffs JL; van Putten WL; Novotny VM; Te Boekhorst PA; Schipperus MR; Zwaginga JJ; van Pampus LC; de Greef GE; Luten M; Huijgens PC; Brand A; van Rhenen DJ;
Br J Haematol; 2010 Jul; 150(2):209-17. PubMed ID: 20507310
[TBL] [Abstract][Full Text] [Related]
2. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.
Lozano M; Knutson F; Tardivel R; Cid J; Maymó RM; Löf H; Roddie H; Pelly J; Docherty A; Sherman C; Lin L; Propst M; Corash L; Prowse C
Br J Haematol; 2011 May; 153(3):393-401. PubMed ID: 21418180
[TBL] [Abstract][Full Text] [Related]
3. Safety and clinical efficacy of platelet components prepared with pathogen inactivation in routine use for thrombocytopenic patients.
Schlenke P; Hagenah W; Irsch J; Sundin D; Corash L; Lin L; Kirchner H; Wagner T
Ann Hematol; 2011 Dec; 90(12):1457-65. PubMed ID: 21503644
[TBL] [Abstract][Full Text] [Related]
4. A randomized study of buffy coat platelets in platelet additive solution stored 1-5 versus 6-7 days prior to prophylactic transfusion of allogeneic haematopoietic progenitor cell transplant recipients.
Diedrich B; Ringdén O; Watz E; Shanwell A
Vox Sang; 2009 Oct; 97(3):254-9. PubMed ID: 19508669
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy of pooled buffy-coat platelet components prepared and stored with a platelet additive solution.
van Rhenen DJ; Gulliksson H; Cazenave JP; Pamphilon D; Davis K; Flament J; Corash L
Transfus Med; 2004 Aug; 14(4):289-95. PubMed ID: 15285725
[TBL] [Abstract][Full Text] [Related]
6. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets.
Janetzko K; Lin L; Eichler H; Mayaudon V; Flament J; Klüter H
Vox Sang; 2004 May; 86(4):239-45. PubMed ID: 15144528
[TBL] [Abstract][Full Text] [Related]
7. Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study.
Simonsen AC; Johansson PI; Conlan MG; Jacquet M; Lin JS; Junge K; Lin L; Sørensen H; Borregaard N; Flament J
Transfusion; 2006 Mar; 46(3):424-33. PubMed ID: 16533286
[TBL] [Abstract][Full Text] [Related]
8. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial.
Snyder E; McCullough J; Slichter SJ; Strauss RG; Lopez-Plaza I; Lin JS; Corash L; Conlan MG;
Transfusion; 2005 Dec; 45(12):1864-75. PubMed ID: 16371039
[TBL] [Abstract][Full Text] [Related]
9. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial.
van Rhenen D; Gulliksson H; Cazenave JP; Pamphilon D; Ljungman P; Klüter H; Vermeij H; Kappers-Klunne M; de Greef G; Laforet M; Lioure B; Davis K; Marblie S; Mayaudon V; Flament J; Conlan M; Lin L; Metzel P; Buchholz D; Corash L;
Blood; 2003 Mar; 101(6):2426-33. PubMed ID: 12456508
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials.
Cid J; Escolar G; Lozano M
Vox Sang; 2012 Nov; 103(4):322-30. PubMed ID: 22563850
[TBL] [Abstract][Full Text] [Related]
11. Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components.
Sigle JP; Infanti L; Studt JD; Martinez M; Stern M; Gratwohl A; Passweg J; Tichelli A; Buser AS
Transfusion; 2013 Aug; 53(8):1788-97. PubMed ID: 23176347
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of platelet function using the in vitro bleeding time and corrected count increment of transfused platelets. Comparison between platelet concentrates derived from pooled buffy coates and apheresis.
Eriksson L; Kristensen J; Olsson K; Bring J; Högman CF
Vox Sang; 1996; 70(2):69-75. PubMed ID: 8801766
[TBL] [Abstract][Full Text] [Related]
13. Clarify the negatives of the MIRASOL noninferiority trial.
Strauss RG
Transfusion; 2011 Jun; 51(6):1361-2; author reply 1362-4. PubMed ID: 21658043
[No Abstract] [Full Text] [Related]
14. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia.
Slichter SJ; Raife TJ; Davis K; Rheinschmidt M; Buchholz DH; Corash L; Conlan MG
Transfusion; 2006 May; 46(5):731-40. PubMed ID: 16686840
[TBL] [Abstract][Full Text] [Related]
15. Leukoreduced buffy coat-derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet A light stored up to 7 days: assessment of hemostatic function under flow conditions.
Lozano M; Galan A; Mazzara R; Corash L; Escolar G
Transfusion; 2007 Apr; 47(4):666-71. PubMed ID: 17381625
[TBL] [Abstract][Full Text] [Related]
16. Assessing the effectiveness of whole blood-derived platelets stored as a pool: a randomized block noninferiority trial.
Heddle NM; Cook RJ; Blajchman MA; Barty RL; Sigouin CS; Boye DM; Nelson EJ; Kelton JG
Transfusion; 2005 Jun; 45(6):896-903. PubMed ID: 15934987
[TBL] [Abstract][Full Text] [Related]
17. [Bacterial contamination: should it be detected or inactivated?].
Cazenave JP
Transfus Clin Biol; 2007 May; 14(1):81-5. PubMed ID: 17521943
[TBL] [Abstract][Full Text] [Related]
18. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria.
Lin L; Dikeman R; Molini B; Lukehart SA; Lane R; Dupuis K; Metzel P; Corash L
Transfusion; 2004 Oct; 44(10):1496-504. PubMed ID: 15383024
[TBL] [Abstract][Full Text] [Related]
19. Reduction in adverse reactions to platelets by the removal of plasma supernatant and resuspension in a new additive solution (M-sol).
Azuma H; Hirayama J; Akino M; Miura R; Kiyama Y; Imai K; Kasai M; Koizumi K; Kakinoki Y; Makiguchi Y; Kubo K; Atsuta Y; Fujihara M; Homma C; Yamamoto S; Kato T; Ikeda H
Transfusion; 2009 Feb; 49(2):214-8. PubMed ID: 18798806
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set.
Janetzko K; Cazenave JP; Klüter H; Kientz D; Michel M; Beris P; Lioure B; Hastka J; Marblie S; Mayaudon V; Lin L; Lin JS; Conlan MG; Flament J
Transfusion; 2005 Sep; 45(9):1443-52. PubMed ID: 16131376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]